Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Change in Accured Expenses data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 80.08% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $2.8 million, up 58.45%, while the annual FY2024 figure was $4.2 million, 17.63% up from the prior year.
  • Change in Accured Expenses reached $4.2 million in Q3 2025 per GLUE's latest filing, up from -$2.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.2 million in Q3 2025 and bottomed at -$3.9 million in Q1 2024.
  • Average Change in Accured Expenses over 3 years is $623454.5, with a median of $2.0 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: soared 186.81% in 2024, then plummeted 220.89% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $1.3 million in 2023, then skyrocketed by 186.81% to $3.7 million in 2024, then grew by 13.44% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $4.2 million in Q3 2025, -$2.5 million in Q2 2025, and -$2.6 million in Q1 2025.